Daily Stock Opinions and Ratings

Opinions

Paul MacDonald Teva Pharmaceutical TEVA-N COMMENT May 03, 2019

There is hope for it. Good news is the generic price declines have subsided, but "less declines" is not where he wants to be right now. Challenged in the next 12-18 months. Could go to low 20s, but structural headwinds for the business.

Paul MacDonald

Unlock Rating

$15.180

Stock price when the opinion was issued

biotechnology pharmaceutical

It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

Get Signals Create your Watchlist

You might be interested:

DON'T BUY

They went from an in incredibly well managed drug company and then management decided to develop their own drugs and make mistakes. It is difficult to unwind these problems. Turning around a company like this will be difficult because of the debt. This is a highly speculative stock.

HOLD

Generic brand companies like Teva have struggled in the last 5 years has they competed with each others. Pfizer is in the process of buying one of their competitors and the Pfizer stock dropped 5$ on the announcement. Doesn't own Teva, purchased United Heatlth recently. You can hold but it's not a name he would hold due to the risk and they have no value added.

BUY

It's time to get back in. They all went crazy and then slid on sympathy when valiant went bust. There is tremendous value here. His model price is $21.26 or 63% upside. They presented earnings and the balance sheet looks great.

DON'T BUY

Doesn't offer growth. The stock is weak and will stay weak.

DON'T BUY

Involved in the opiate crisis. Balance sheet is weak. Overall topline growth is low. Stay away. A lot of problems still to overcome.

DON'T BUY

Tends to avoid companies with a ton of debt. Management missteps, and investors are paying for those. In the depths of a tough turnaround. He'd rather own a VTRS, where the debt is manageable, balance sheet's in better shape, with a better growth trajectory.

DON'T BUY

He's put the white flag up on this one. It's about macro interest rates, currency moves. Don't waste your time with these story stocks. His model price is $18.80, and it could have all the fundamentals, but the macro waves swamp the boat. Go with the big names.

BUY ON WEAKNESS

Has owned company for a long period of time in the past. Previous reasons for owning stock not present anymore. Waiting to see if new drugs are invented/patented.

DON'T BUY

Massive share price appreciation not sustainable.
Large debt load presents difficulties.
Does not own shares.
Would not recommend buying at this time.

DON'T BUY

It's cheap and has momentum, but that's all it has now. It never grabbed him.

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

Paul MacDonald Teva Pharmaceutical TEVA-N COMMENT May 03, 2019

You might be interested:

Teva Pharmaceutical(TEVA-N)

Teva Pharmaceutical(TEVA-N)

Teva Pharmaceutical(TEVA-N)

Teva Pharmaceutical(TEVA-N)

Teva Pharmaceutical(TEVA-N)

Teva Pharmaceutical(TEVA-N)

Teva Pharmaceutical(TEVA-N)

Teva Pharmaceutical(TEVA-N)

Teva Pharmaceutical(TEVA-N)

Teva Pharmaceutical(TEVA-N)

Latest Buy Signals

Today's Top Picks

Popular Articles

Latest Sell Signals

Most Recent Experts

Bruce Murray

The Panic-Proof Portfolio (Stockchase Research)

The Weekly Buzzing Stocks by Billy Kawasaki

Chris Blumas

Stockchase Insights